All In MedTech

Device Trial Radar · NCT03969862

Validation Study of NOVEOS® System (HYCOR)

Validation Study of Noveos® System as a Diagnostic Tools for Allergy

Last checked: Nov 19, 2026Latest source record: Jun 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

536

Actual

Start

Dec 4, 2019

Primary completion

Mar 10, 2020

Study completion Mar 10, 2020

Sponsor

Lead sponsor
University Hospital, MontpellierAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hycor Biomedical
First posted
May 31, 2019

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background : The NOVEOS® method is a chemiluminescent immunoassay used to provide quantitative detection of total IgE and allergen-specific IgE antibodies in human serum. The IgE antibody assay has an essential place in the diagnosis of mediated IgE allergies. This system could become an alternative to the techniques used today. NOVEOS® uses a quick and convenient method to give results concerning the patient's sensitization profile towards allergens. The volume required for the assays is 4 μl (against more than 100 μl for current techniques), which is particularly important in pediatric and geriatric populations where it may be more difficult to take larger samples. NOVEOS® also brings true autonomy. In fact, the incorporated reagents provide sufficient capacity for 8 hours of continuous testing. Objective: Validate the NOVEOS® system as an allergy diagnostic tool, by estimating the sensitivity and specificity of the NOVEOS® assays compared to the gold standard diagnostic represented by the clinical history and PT positive, for a panel of 20 allergens Methods: This is a validation study of a new immunoassay method (Système NOVEOS®). The study includes : * A preliminary phase to familiarize the team with the use of the NOVEOS® system. It is planned to analyze its technical characteristics: the precision, the sensitivity. Eight allergens will be tested, on a cohort of 136 patients * A validation study of the technique as a diagnostic tool for allergy (sensitivity and specificity compared to the gold standard represented by clinical history and positive PT) and comparison between the new technique and the ImmunoCap® system. Twenty allergens will be tested prospectively, each on 50 cases and 10 controls. A single patient may be both a case for an allergen and a witness for another. For rare allergies, the blood database of the Allergy Service will be used, and affected patients will be contacted to request their non-opposition.

Conditions

  • Allergen-mediated IgE Allergy

Interventions

  • NOVEOS® systemDevice

    The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase. This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity and specificity of the NOVEOS® assay compared to the gold standard diagnosis.Time frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital of Montpellier

    Montpellier, Occitanie, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.